Ann: FY23 Results Presentation, page-2

Here is a company that just continues to execute. While many management teams turn into victims and focus their time and efforts on explaining to shareholders all the things that happened to them and harmed their results... PBP just gets on with it.

My favorite quote from the preso
" Revenue growth of 17% driven by recovery of virus-related markets together with pricing uplifts to recoup inflationary cost pressures"

No whinging or failure explanations... if costs are up and margins are squeezed they simply raise prices, in time to matter, since they are driving so much new business in. Excellent execution. Oh and they have significant excess capacity in their new facility so we may also enjoy better scale benefits over time. They seem to suggest that when these companies are on-shoring their pharma production the lead variable is not cost but certainty of supply. And act accordingly.

Cuppa